WO2007030451A3 - Anticorps utilises comme mimetiques de recepteurs de lymphocytes t, leurs methodes de production et leurs applications - Google Patents
Anticorps utilises comme mimetiques de recepteurs de lymphocytes t, leurs methodes de production et leurs applications Download PDFInfo
- Publication number
- WO2007030451A3 WO2007030451A3 PCT/US2006/034547 US2006034547W WO2007030451A3 WO 2007030451 A3 WO2007030451 A3 WO 2007030451A3 US 2006034547 W US2006034547 W US 2006034547W WO 2007030451 A3 WO2007030451 A3 WO 2007030451A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- antibodies
- mhc
- cell receptor
- interest
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06814164A EP1933864A4 (fr) | 2005-09-07 | 2006-09-07 | Anticorps utilisés comme mimétiques de récepteurs de lymphocytes t, leurs méthodes de production et leurs applications |
AU2006289683A AU2006289683A1 (en) | 2005-09-07 | 2006-09-07 | Antibodies as T cell receptor mimics, methods of production and uses thereof |
CA002662798A CA2662798A1 (fr) | 2005-09-07 | 2006-09-07 | Anticorps utilises comme mimetiques de recepteurs de lymphocytes t, leurs methodes de production et leurs applications |
IL190014A IL190014A0 (en) | 2005-09-07 | 2008-03-06 | Antibodies as t cell receptor mimics, methods of production and uses thereof |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71462105P | 2005-09-07 | 2005-09-07 | |
US60/714,621 | 2005-09-07 | ||
US75154205P | 2005-12-19 | 2005-12-19 | |
US60/751,542 | 2005-12-19 | ||
US75273705P | 2005-12-20 | 2005-12-20 | |
US60/752,737 | 2005-12-20 | ||
US83827606P | 2006-08-17 | 2006-08-17 | |
US60/838,276 | 2006-08-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007030451A2 WO2007030451A2 (fr) | 2007-03-15 |
WO2007030451A3 true WO2007030451A3 (fr) | 2009-04-16 |
Family
ID=37836380
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/034547 WO2007030451A2 (fr) | 2005-09-07 | 2006-09-07 | Anticorps utilises comme mimetiques de recepteurs de lymphocytes t, leurs methodes de production et leurs applications |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1933864A4 (fr) |
AU (1) | AU2006289683A1 (fr) |
CA (1) | CA2662798A1 (fr) |
IL (1) | IL190014A0 (fr) |
WO (1) | WO2007030451A2 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007143104A2 (fr) * | 2006-06-01 | 2007-12-13 | Receptor Logic, Ltd. | Anticorps utiles en tant qu'analogues de récepteur des lymphocytes t, leurs procédés de production et leurs utilisations |
WO2009108372A2 (fr) * | 2008-02-27 | 2009-09-03 | Receptor Logic, Inc. | Anticorps imitant les récepteurs des lymphocytes t, leurs procédés de production et d’utilisation |
UA114108C2 (uk) | 2012-07-10 | 2017-04-25 | Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем | Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5679641A (en) * | 1992-05-26 | 1997-10-21 | Rijksuniversiteit Leiden | Peptides of human P53 protein for use in human T cell response inducing compositions, and human P53 protein-specific cytotoxic t-lymphocytes |
US5726023A (en) * | 1993-03-17 | 1998-03-10 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated |
US5968513A (en) * | 1996-06-24 | 1999-10-19 | University Of Maryland Biotechnology Institute | Method of promoting hematopoiesis using derivatives of human chorionic gonadotropin |
US20030165513A1 (en) * | 2000-12-04 | 2003-09-04 | Venky Ramakrishna | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
US20030223994A1 (en) * | 2002-02-20 | 2003-12-04 | Hoogenboom Henricus Renerus Jacobus Mattheus | MHC-peptide complex binding ligands |
US20040191260A1 (en) * | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
WO2004101607A2 (fr) * | 2003-05-13 | 2004-11-25 | Hildebrand William H | Representation cartographique comparative de ligands a partir de cellules positives de classe i du cmh |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1319184B1 (fr) * | 2000-08-14 | 2007-07-25 | N.V. Organon | Utilisation d'anticorps contre des complexes de peptides mhc specifiques |
FR2839452A1 (fr) * | 2002-05-07 | 2003-11-14 | Pf Medicament | Utilisation de peptide derive de la sous-unite beta de l'hcg pour generer une reponse de type ctl antitumorale |
WO2005116072A2 (fr) * | 2004-05-27 | 2005-12-08 | Weidanz Jon A | Anticorps mimetiques de recepteurs de cellules t et leurs procedes de production et d'utilisation |
-
2006
- 2006-09-07 AU AU2006289683A patent/AU2006289683A1/en not_active Abandoned
- 2006-09-07 CA CA002662798A patent/CA2662798A1/fr not_active Abandoned
- 2006-09-07 EP EP06814164A patent/EP1933864A4/fr not_active Withdrawn
- 2006-09-07 WO PCT/US2006/034547 patent/WO2007030451A2/fr active Application Filing
-
2008
- 2008-03-06 IL IL190014A patent/IL190014A0/en unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5679641A (en) * | 1992-05-26 | 1997-10-21 | Rijksuniversiteit Leiden | Peptides of human P53 protein for use in human T cell response inducing compositions, and human P53 protein-specific cytotoxic t-lymphocytes |
US5726023A (en) * | 1993-03-17 | 1998-03-10 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated |
US5968513A (en) * | 1996-06-24 | 1999-10-19 | University Of Maryland Biotechnology Institute | Method of promoting hematopoiesis using derivatives of human chorionic gonadotropin |
US20030165513A1 (en) * | 2000-12-04 | 2003-09-04 | Venky Ramakrishna | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
US20030223994A1 (en) * | 2002-02-20 | 2003-12-04 | Hoogenboom Henricus Renerus Jacobus Mattheus | MHC-peptide complex binding ligands |
US20040191260A1 (en) * | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
WO2004101607A2 (fr) * | 2003-05-13 | 2004-11-25 | Hildebrand William H | Representation cartographique comparative de ligands a partir de cellules positives de classe i du cmh |
Also Published As
Publication number | Publication date |
---|---|
EP1933864A4 (fr) | 2009-12-16 |
IL190014A0 (en) | 2008-08-07 |
WO2007030451A2 (fr) | 2007-03-15 |
CA2662798A1 (fr) | 2007-03-15 |
EP1933864A2 (fr) | 2008-06-25 |
AU2006289683A1 (en) | 2007-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005116072A3 (fr) | Anticorps mimetiques de recepteurs de cellules t et leurs procedes de production et d'utilisation | |
CA2907050C (fr) | Procedes de detection de liaison peptide/mhc/tcr | |
Bharadwaj et al. | Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex | |
Bodd et al. | HLA-DQ2-restricted gluten-reactive T cells produce IL-21 but not IL-17 or IL-22 | |
US20200103408A1 (en) | Method for the absolute quantification of naturally processed hla-restricted cancer peptides | |
Schirle et al. | Combining computer algorithms with experimental approaches permits the rapid and accurate identification of T cell epitopes from defined antigens | |
CA2793490A1 (fr) | Differenciation quantitative de peptides a restriction hla traites naturellement dans le but de developper une immunotherapie pour les cancers, les maladies auto-immunes et les maladies infectieuses | |
Shahine et al. | A T-cell receptor escape channel allows broad T-cell response to CD1b and membrane phospholipids | |
Dørum et al. | HLA-DQ molecules as affinity matrix for identification of gluten T cell epitopes | |
Archila et al. | Grass‐specific CD 4+ T‐cells exhibit varying degrees of cross‐reactivity, implications for allergen‐specific immunotherapy | |
Fulton et al. | Immunoproteomics: current technology and applications | |
US10478482B2 (en) | Vaccines for prevention and treatment of tuberculosis | |
Sollid et al. | Small bowel, celiac disease and adaptive immunity | |
CN112739708A (zh) | 对与主要组织相容性复合体结合的肽进行单分子测序 | |
WO2007030451A3 (fr) | Anticorps utilises comme mimetiques de recepteurs de lymphocytes t, leurs methodes de production et leurs applications | |
Gengenbacher et al. | Mycobacterium tuberculosis in the Proteomics Era | |
ES2463828T3 (es) | Polipéptidos híbridos hipoalergénicos para el tratamiento de alergia | |
Wang et al. | Recent progress on MHC-I epitope prediction in tumor immunotherapy | |
Graner et al. | The ‘peptidome’of tumour-derived chaperone-rich cell lysate anti-cancer vaccines reveals potential tumour antigens that stimulate tumour immunity | |
Margulies et al. | MHC class I/peptide interactions: binding specificity and kinetics | |
Inoue et al. | Discovery of an α2, 9-polyNeu5Ac glycoprotein in C-1300 murine neuroblastoma (clone NB41A3) | |
Wahl et al. | Direct class I HLA antigen discovery to distinguish virus-infected and cancerous cells | |
WO2022133347A2 (fr) | Exposition de peptide-mhc (pmhc) sur des échafaudages protéiques multimères et leurs utilisations | |
WO2006138449A3 (fr) | Procede d'identification d'un antigene de cellules auxiliaires associe a des tumeurs dependant du cmh de classe 2 | |
Stenvall et al. | High-throughput solubility assay for purified recombinant protein immunogens |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 190014 Country of ref document: IL |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006289683 Country of ref document: AU Ref document number: 2006814164 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006289683 Country of ref document: AU Date of ref document: 20060907 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2662798 Country of ref document: CA |